Washington, DC 20006-5349
HELPLINE
Despite initial positive signs from its phase 2 counterpart, the phase 3 LUME-Meso trial in malignant pleural mesothelioma did not meet its primary endpoint of…
The short answer is: no. Maintenance pemetrexed (Alimta) following standard treatment of pemetrexed (Alimta)/cisplatin does not prolong progression-free survival in patients with pleural mesothelioma. It…
On Tuesday, November 13, we hosted our Meet the Mesothelioma Experts live broadcast with Dr. Marjorie Zauderer, of Memorial Sloan Kettering Cancer Center and chair…
The National Cancer Institute recently announced that it will be funding a five-year, $10.7 million grant for research into how chimeric antigen receptor (CAR)-T cells…
For the first time in mesothelioma, a group of researchers sequenced the genome of 74 malignant pleural mesothelioma tumors. According to the authors, the study…
We are deeply saddened by the passing of Dr. David Sugarbaker, a beloved mesothelioma surgeon and researcher. He leaves a huge void in the mesothelioma…
UPDATE: This study has been completed with the full analysis of all 54 patients. Click here for full results. Earlier this month, during the most…
Yesterday, at the annual meeting of the American Society of Gene and Cell Therapy in Chicago, researchers from Memorial Sloan Kettering Cancer Center released a…
A new article reviewing progress and advances that occurred in 2017 in the management of pleural mesothelioma was just published in the May 2018 issue…
In 2004, over 14 years ago (!), the FDA approved the first ever (and the last so far) mesothelioma treatment drug – Alimta (pemetrexed) in…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
